Analysis Of Cancer-testis Antigens As Molecular Drug Targets Using Network Pharmacology | 38945
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Analysis of cancer-testis antigens as molecular drug targets using network pharmacology

6th World Congress on Biotechnology

Anuj Kumar

Shriram Institute for Industrial Research, India

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.043

Present chemotherapeutic drugs have limited efficacy and sever side effects. Considering the complexity of cancer, an effective strategy is to discover multiple new drug targets. Cancer testis antigens are vital of cancer cell progression and drugs targeting these proteins should have no toxicity. We have performed network analysis of cancer testis antigens and assessed nodes as drug targets based on its position in the network. We have analyzed the protein interaction network of 700 human CT antigens based on available information on STRING 9.1 database. CT antigen network consisted of eight independent components. Four major hubs and two minor were identified that play nodal role in flow of information across the largest network. We have predicted 30 potential drug targets by analyzing topological parameters such as betweenness centrality, cluster coefficient and probable protein complexes. Structural and functional roles of potential drug targets were analyzed. Analysis of CT antigen network enables us to identify a set of candidate proteins that if targeted could be detrimental for cancerous cell without affecting any normal cell. The list of putative proteins is a starting point for experimental validation and further discovery of new anti-cancer drugs.

Anuj Kumar has completed his PhD under the supervision of Dr. Amit Sharma, ICGEB, JNU and completed his Postdoctoral studies with Dr. Chetan E. Chitnis, Malaria Biology Group, ICGEB. He is currently working as Head of Molecular Biology Lab in Shriram Institute for Industrial Research, Delhi.

Email: [email protected]